Injectable enzyme appears effective in treating Peyronie's disease
An investigational injectable enzyme known as AA4500 appears to be effective and generally well tolerated in treating patients with Peyronie's disease, according to data from two phase II open-label trials presented at the recent AUA Western Section annual meeting in Maui, HI.
Jessica Feehan, NP-C, discusses the expanding role of APPs in urology, from clinical leadership and procedures to care coordination and treatment initiation.
Sam S. Chang, MD, MBA, discusses treatment selection after BCG failure, including bladder-sparing options, cystectomy considerations, and the need for sequencing data.
Justin B. Ziemba, MD, discusses clinical factors that help identify patients at increased risk for kidney stone recurrence and guide metabolic evaluation.
Adam Sharp, PhD, BM, MRCP, BSc, discusses preliminary safety and efficacy findings from a phase 1/2 study of gedatolisib plus darolutamide in patients with mCRPC.